1.1                          A bill for an act
  1.2             relating to human services; providing medical 
  1.3             assistance reimbursement for a comprehensive 
  1.4             pharmaceutical care research project. 
  1.5   BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA: 
  1.6      Section 1.  [COMPREHENSIVE PHARMACEUTICAL CARE RESEARCH 
  1.7   PROJECT.] 
  1.8      Subdivision 1.  [DEFINITIONS.] For the purposes of this 
  1.9   section, the following terms have the meanings given them.  
  1.10     (a) "Comprehensive pharmaceutical care" means the 
  1.11  responsible provision of drug therapy in order to identify, 
  1.12  prevent, and resolve drug therapy problems and achieve positive 
  1.13  patient outcomes.  Comprehensive pharmaceutical care is provided 
  1.14  only when the pharmacist delivers the following basic services: 
  1.15     (1) patient consultation; 
  1.16     (2) assessment; 
  1.17     (3) care planning; 
  1.18     (4) patient education, recommendations, and referrals; and 
  1.19     (5) patient monitoring and follow-up. 
  1.20     (b) "Institute" means the Peters' Institute of 
  1.21  Pharmaceutical Care within the College of Pharmacy, University 
  1.22  of Minnesota. 
  1.23     Subd. 2.  [MEDICAL ASSISTANCE REIMBURSEMENT.] The 
  1.24  commissioner of human services shall enter into an agreement 
  1.25  with the institute to provide medical assistance reimbursement 
  2.1   for up to one year for comprehensive pharmaceutical care 
  2.2   services.  Reimbursement for comprehensive pharmaceutical care 
  2.3   services must be limited to services provided to medical 
  2.4   assistance enrollees by pharmacies currently participating in 
  2.5   the Minnesota pharmaceutical care project.  Reimbursement must 
  2.6   be based on a schedule consistent with the resource based 
  2.7   relative value scale (RBRVS) developed and evaluated through the 
  2.8   Minnesota pharmaceutical care project. 
  2.9      Subd. 3.  [INSTITUTE RESPONSIBILITIES.] The commissioner of 
  2.10  human services, as part of this agreement, shall request the 
  2.11  institute to: 
  2.12     (1) expand the Minnesota pharmaceutical care project to 
  2.13  include medical assistance recipients at some or all of the 
  2.14  participating pharmacies; 
  2.15     (2) extend the data collection period for the medical 
  2.16  assistance population beyond the project completion date for the 
  2.17  nonmedical assistance population, in order to allow data on 
  2.18  medical assistance recipients to be collected for at least six 
  2.19  months but not exceeding one year; 
  2.20     (3) evaluate the impact of comprehensive pharmaceutical 
  2.21  care on the identification, prevention, and resolution of drug 
  2.22  therapy problems among medical assistance recipients, and on 
  2.23  medical assistance costs; 
  2.24     (4) regularly consult with the commissioner, and make study 
  2.25  data on medical assistance recipients and comparison groups 
  2.26  available to the commissioner upon completion of the study; and 
  2.27     (5) present recommendations to the commissioner by January 
  2.28  15, 1997, on whether the comprehensive pharmaceutical care model 
  2.29  should be extended to additional medical assistance recipients.